BCR and acute myeloid leukemia: Dasatinib, an FDA-approved multi-targeted kinase inhibitor of BCR/ABL and Src kinases [31] was reported to induce ERK phosphorylation in acute myeloid leukemia (AML) [32] and during stimulated pigmentation of ex vivo cultured skin [33].